Table 1 The clinical characteristics, treatment and outcomes of 13 patients with metastatic GTN without primary lesions
Patients No | Age | G/P | Symptoms | Signs | Antecedent pregnancy | Interval (months) | Pretreatment hCG(IU/L) | Initial disposition | Metastasis site |
|---|---|---|---|---|---|---|---|---|---|
1 | 28 | 3/1 | Vaginal bleeding | Lung mass | Mole | 17 | 2021 | GTN | Right lung |
2 | 31 | 1/0 | Vaginal bleeding | Lung mass | Mole | 3 | 121 | GTN | Right lung |
3 | 23 | 2/0 | None | Lung mass | Abortion | 11 | 277 | Ectopic pregnancy | Right lung |
4 | 32 | 4/2 | Vaginal bleeding, cough | None | Term | 3 | 194 | Lung cancer | Right lung |
5 | 30 | 1/0 | Vaginal bleeding | Lung mass | Mole | 14 | 144 | GTN | Right lung |
6 | 27 | 2/0 | Vaginal bleeding | Lung mass | Abortion | 36 | 967 | Ectopic pregnancy | Right lung |
7 | 36 | 3/1 | Vaginal bleeding | None | Abortion | 60 | 1100 | Ectopic pregnancy | Left lung |
8 | 31 | 1/0 | Vaginal bleeding | Ovarian mass | Abortion | 108 | 612 | Ectopic pregnancy | Left ovary |
9 | 19 | 0/0 | Vaginal bleeding | Ovarian mass | Abortion | N/A | 104,400 | Ectopic pregnancy | Right ovary |
10 | 37 | 2/0 | None | Lung and breast mass | Abortion | 60 | 21,136 | Lung cancer, breast cancer | Left lung, kidney, brain, breast, liver, waist quadratus |
11 | 41 | 5/2 | None | Adnexal mass | Abortion | 5 | > 2000 | Ectopic pregnancy | Right pelvic funnel ligament and mesocolon |
12 | 36 | 5/1 | Abdominal pain | Adnexal mass | Abortion | 34 | 119 | Ovary tumor | Masses on the right ovary, omentum, and abdominal wall |
13 | 26 | 0/0 | None | Ovarian and liver masses | Pregnancy (29 weeks) | 7 | 807,270 | Ovary tumor | The right lung, pelvic abdomen, liver |
Patients No | Number of metastases | Initial treatment | Definitive diagnostic method | Pathological diagnosis | FIGO stage | Prognostic score | Chemotherapy | The number of consolidation chemotherapy | Relapse |
|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 5 cycles of TP | VATS | ETT | III | / | 2 cycles of EP-EMA + 5 cycles of EP | 5 | No |
2 | 1 | D&C | VATS | CC | III | 5 | 6 cycles of MTX | N/A | No |
3 | 1 | D&C + Laparoscopy | VATS | ETT | III | / | 3 cycles of EP-EMA | 3 | No |
4 | 1 | D&C + Laparoscopy | VATS | ETT | III | / | 3 cycles of EP-EMA | 3 | No |
5 | 1 | PTNB | VATS | ETT | III | / | 3 cycles of EMA-CO | 3 | No |
6 | 1 | PTNB | VATS | CC | III | 5 | 6 cycles of MTX | 3 | Yes |
7 | 1 | D&C + Laparoscopy + 1 cycle of MTX | VATS | CC | III | 7 | 3 cycles of TP | 3 | No |
8 | 1 | Laparoscopy + 1 cycle of MTX | LOCR | CC | II | 7 | 3 cycles of EMA-CO + 3 cycles of EP-EMA + 4 cycles of FAEV | 5 | Yes |
9 | 1 | Laparoscopy | LOCR | CC | II | > 7 | 7 cycles of EMA-CO | 3 | No |
10 | Multiple | VATS + SM | VATS + SM | CC | IV | 17 | 2 cycles of EMA-CO + 8 cycles of EP-EMA + 2 cycles of MTX intrathecal injection | 5 | Yes |
11 | Multiple | Laparoscopy + 2 cycles of MTX | LMR | CC | II | 9 | 3 cycles of EMA-CO + 2 cycles of EMA | 3 | No |
12 | Multiple | D&C + Laparoscopy | LUA + LMR | CC/ETT | IV | 12 | 4 cycles of EP-EMA | 3 | No |
13 | Multiple | Cesarean | Cytoreductive surgery | CC | IV | 7 | 5 cycles of EMA-CO | N/A | No |